11. MCG 2.0: A highly curated, scalable precision cancer medicine resource

Identification of genetic abnormalities has become an important component of cancer diagnosis, risk stratification, and treatment planning, and many types of advanced or metastatic cancers are now routinely sequenced to identify mutations that may confer drug sensitivity or resistance. However, evaluating the clinical significance of the alterations identified by these assays can be difficult, especially as assays expand to characterize increasing amounts of genetic material. My Cancer Genome was initially launched in 2011 by the Vanderbilt-Ingram Cancer Center as the first web-based precision cancer medicine knowledge source, providing both up-to-date information on clinically relevant mutations in cancer and clinical trial options for patients with selected alterations.

Source: Cancer Genetics and Cytogenetics - March 31, 2019 Category: Genetics & Stem Cells Authors: Marilyn Holt, Christine Micheel, Ingrid Anderson, Michele LeNoue-Newton, Neha Jain, Clinton Miller, Michelle Botyrius, Ian Maurer, Justin Yeakley, Lori Vanelli, Mia Levy Source Type: research